US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Savara, Inc. - Common Stock (NQ:SVRA)

4.220 -0.320 (-7.05%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Savara, Inc. - Common Stock

< Previous 1 2 Next >
Top movers in Tuesday's after hours session ↗
Via Chartmill
News headline image
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline ↗
This clinical-stage biotech focused on rare lung diseases reported significant insider selling amid a year of strong share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
SVRA Stock Earnings: Savara Misses EPS for Q2 2024 ↗
SVRA stock results show that Savara missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
SVRA Stock Earnings: Savara Misses EPS for Q1 2024 ↗
SVRA stock results show that Savara missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
SVRA Stock Earnings: Savara Beats EPS for Q4 2023 ↗
SVRA stock results show that Savara beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation. 
Via The Motley Fool
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy ↗
The company is seeking approval for Molbreevi to treat patients with Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP). 
Via Stocktwits
Topics Intellectual Property Lawsuit
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
This Starbucks Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday? ↗
Savara's Molbreevi BLA for autoimmune PAP was rejected by the FDA due to incomplete CMC data; the company plans to resubmit in Q4 2025. 
Via Benzinga
News headline image
Here are the top movers in Tuesday's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April ↗
 
Via Benzinga
Topics Stocks
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings ↗
 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday? ↗
Savara announces Phase 3 IMPALA-2 trial results for molgramostim in treating autoimmune pulmonary alveolar proteinosis. The inhaled GM-CSF met primary and secondary endpoints, showing significant... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning! 
Via InvestorPlace
News headline image
3 Penny Stocks Poised for Major Upside Over the Next 5 Years ↗
These three penny stocks to buy are poised for major upside over the medium-term, for various reasons worth exploring. 
Via InvestorPlace
News headline image
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition ↗
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 200 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
5 OTC Stocks With The Potential To Explode In 2024 ↗
Investors who are ready to dive into the OTC pool have more options than ever, both with the number of stocks to choose from and available investing platforms. 
Via Benzinga
< Previous 1 2 Next >